

Resource Summary Report

Generated by [RRID](#) on Sep 2, 2026

OCI-Ly1

RRID:CVCL_1879

Type: Cell Line

Proper Citation

RRID:CVCL_1879

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1879

Proper Citation: RRID:CVCL_1879

Description: Cell line OCI-Ly1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Diffuse large B-cell lymphoma

Defining Citation: [PMID:3567358](#), [PMID:8574164](#), [PMID:10676951](#), [PMID:11807979](#), [PMID:12169673](#), [PMID:19278952](#), [PMID:19358282](#), [PMID:20628145](#), [PMID:23257783](#), [PMID:23292937](#), [PMID:23699601](#), [PMID:25960936](#)

Comments: From: Ontario Cancer Institute (OCI); Toronto; Canada.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-Ly1

Synonyms: OCI-LY1, OCI-ly1, OCI-LY-1, OCI-Ly-1, Oci-Ly-1, OCI-Ly 1, OCI-Ly01, OCI Ly1, Ly1, LY1

Cross References: EFO:EFO_0005907, BioGRID_ORCS_Cell_line:1211, cancercellines:CVCL_1879, ChEMBL-Cells:ChEMBL4295427, ChEMBL-Targets:ChEMBL4296480, Cosmic:1134602, Cosmic:1295512, Cosmic:1329091, Cosmic:1517641, Cosmic:1541900, Cosmic:1629932, Cosmic:1636682, Cosmic:1945183, Cosmic:2276318, DSMZ:ACC-722, DSMZCellDive:ACC-722, ENCODE:ENCBS397COL, ENCODE:ENCBS729LWO, ENCODE:ENCBS899DSB, ENCODE:ENCBS945KYE, GEO:GSM1957, GEO:GSM380130, GEO:GSM552450, GEO:GSM1035341, GEO:GSM1059803, GEO:GSM1374783, GEO:GSM3150250, Lonza:1352,

PRIDE:PXD012087, Progenetix:CVCL_1879, PubChem_Cell_line:CVCL_1879, Wikidata:Q54931759

ID: CVCL_1879

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235504+0000

Ratings and Alerts

No rating or validation information has been found for OCI-Ly1.

No alerts have been found for OCI-Ly1.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Jha RK, et al. (2026) Dynamic Supercoiling Sponsors Transcription Amplification by MYC. bioRxiv : the preprint server for biology.

Demel UM, et al. (2026) Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(17), e11449.

Enssle JC, et al. (2026) Pathogenesis of diffuse large B cell lymphoma proteogenotypes. Cancer cell, 44(7), 1437.

Qiao Q, et al. (2025) Metabolism-related ALDH1B1 acts as potential predictor and therapeutic target for primary gastrointestinal diffuse large B-cell lymphoma. Apoptosis : an international journal on programmed cell death, 30(5-6), 1482.

Isshiki Y, et al. (2025) EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer cell, 43(1), 49.

Rossi A, et al. (2025) Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. iScience, 28(5), 112333.

Dang D, et al. (2025) Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. Cancer cell, 43(6), 1159.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy.

Cancer research.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T??cells targeting CD80/86-upregulated DLBCL. *Cell reports. Medicine*, 5(2), 101421.

He MY, et al. (2024) GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. *Leukemia*, 38(10), 2210.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. *Cancer cell*, 42(5), 833.

Scuoppo C, et al. (2024) Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma. *Blood cancer discovery*, 5(6), 417.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. *Research square*.

Zhuang X, et al. (2024) Functional genomics identifies N-acetyllactosamine extension of complex N-glycans as a mechanism to evade lysis by natural killer cells. *Cell reports*, 43(4), 114105.

Gro?? E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. *Cancers*, 15(11).

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. *Cancer research communications*, 3(4), 576.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. *Cancer discovery*, 13(8), 1862.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. *Cancer discovery*, 13(1), 216.

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. *Molecules (Basel, Switzerland)*, 28(13).